ABSTRACT
Omic technologies and biomarkers development have been largely based on advances in vascular biology, improved understanding of the molecular basis and biochemical pathways responsible for the clinically relevant diseases, and increasingly robust large cohort and/or registry-based studies. Omic technologies adopt a holistic view of the molecules that make up a cell, tissue, or organism. They are aimed primarily at the universal detection of genes, messenger RNA, proteins, and metabolites in a specific biological sample in a nontargeted and nonbiased manner. Coagulation disorders in pregnancy include different clinical conditions, ranging from maternal thromboembolism to a wide spectrum of placenta-mediated complications such as preeclampsia, fetal growth restriction (FGR), stillbirth, and placental abruption. Maternal thromboembolism and a spectrum of placenta-mediated complications including preeclampsia, FGR, fetal loss, and abruption manifest a shared etiopathogenesis and predisposing risk factors.
